About: Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza Part II: Future compounds against influenza virus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza Part II: Future compounds against influenza virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza Part II: Future compounds against influenza virus
Creator	Amicizia, D Gasparini, R Lai, P Bragazzi, N Panatto, D
source	Medline; PMC
abstract	In the first part of this overview, we described the life cycle of the influenza virus and the pharmacological action of the currently available drugs. This second part provides an overview of the molecular mechanisms and targets of still-experimental drugs for the treatment and management of influenza. Briefly, we can distinguish between compounds with anti-influenza activity that target influenza virus proteins or genes, and molecules that target host components that are essential for viral replication and propagation. These latter compounds have been developed quite recently. Among the first group, we will focus especially on hemagglutinin, M2 channel and neuraminidase inhibitors. The second group of compounds may pave the way for personalized treatment and influenza management. Combination therapies are also discussed. In recent decades, few antiviral molecules against influenza virus infections have been available; this has conditioned their use during human and animal outbreaks. Indeed, during seasonal and pandemic outbreaks, antiviral drugs have usually been administered in mono-therapy and, sometimes, in an uncontrolled manner to farm animals. This has led to the emergence of viral strains displaying resistance, especially to compounds of the amantadane family. For this reason, it is particularly important to develop new antiviral drugs against influenza viruses. Indeed, although vaccination is the most powerful means of mitigating the effects of influenza epidemics, antiviral drugs can be very useful, particularly in delaying the spread of new pandemic viruses, thereby enabling manufacturers to prepare large quantities of pandemic vaccine. In addition, antiviral drugs are particularly valuable in complicated cases of influenza, especially in hospitalized patients. To write this overview, we mined various databases, including Embase, PubChem, DrugBank and Chemical Abstracts Service, and patent repositories.
has issue date	2014-12-01(xsd:dateTime)
bibo:pmid	26137785
has license	cc-by-nc-nd
sha1sum (hex)	544a005c6288491bc6229435fddcdec62d6e24b9
resource representing a document's title	Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza Part II: Future compounds against influenza virus
has PubMed Central identifier	PMC4718316
has PubMed identifier	26137785
schema:publication	J Prev Med Hyg
resource representing a document's body	covid:544a005c6288491bc6229435fddcdec62d6e24b9#body_text
is schema:about of	named entity 'PRESENT' named entity 'INFLUENZA VIRUS' named entity 'ACTIVITY' named entity 'STRATEGIES' named entity 'TREATMENT' named entity 'FUTURE' named entity 'OPTIMAL' named entity 'INFLUENZA' named entity 'MANAGEMENT' named entity 'influenza virus' named entity 'influenza viruses' named entity 'paracetamol' named entity 'apoptosis' named entity 'H5N1' named entity 'anti-apoptotic' named entity 'bioinformatics' named entity 'adverse side effects' named entity 'omeprazole' named entity 'mutation' named entity 'morbidity' named entity 'autophagocytosis' named entity 'poliovirus' named entity 'ISGs' named entity 'proteases' named entity 'virus' named entity 'NDV' named entity 'adenoviruses' named entity 'Sphingosine' named entity 'pro-inflammatory molecules' named entity 'epidemics' named entity 'Embase' named entity 'nanoparticles' named entity 'spermidine' named entity 'interferon' named entity 'ascomycete' named entity 'type 2' named entity 'naproxen' named entity 'vRNP' named entity 'Human Rhinovirus' named entity 'NOX2' named entity 'inhibitory activity' named entity 'thermodynamic integration' named entity 'antiviral' named entity 'influenza virus' named entity 'Curcumin' named entity 'vaccine adjuvants' named entity 'oseltamivir' named entity 'Polyamines' named entity 'influenza virus' named entity 'influenza' named entity 'TNF-α' named entity 'oseltamivir' named entity 'viral protein' named entity 'peptide' named entity 'macrophage' named entity 'antiviral' named entity 'ROS' named entity 'CC chemokine' named entity 'cyclic guanosine monophosphate' named entity 'host cell' named entity 'immune response' named entity 'virus' named entity 'monomers' named entity 'influenza' named entity 'biophysical' named entity 'Mx1 protein' named entity 'personalized treatment' named entity 'natural products' named entity 'antiviral' named entity 'Clarithromycin' named entity 'innate immunity' named entity 'autophagy' named entity 'Coughing' named entity 'signaling cascades' named entity 'IFN' named entity 'tissue injury' named entity 'proline' named entity 'drug treatment' named entity 'HIV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software